AZD8965 / AstraZeneca - LARVOL DELTA

Arginase inhibitor AZD8965: A novel therapeutic approach for idiopathic pulmonary fibrosis (ERS 2025) - No abstract available

Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants (clinicaltrials.gov) - P1 | N=163 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open